---
title: "Lysergide (DT120) in Generalized anxiety disorder: LSD-assist"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: LSD-assist. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 57 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence/lsd-assist"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: LSD-assist

<a id="heading-3.1.4"></a>

## 3.1.4 LSD-assist

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Registered objective

> “Objective: To test the efficacy of LSD in patients with anxiety with or without life-threatening diseases.”
> “This study will evaluate the potential benefits of single treatments with LSD in anxiety disorder.”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.1-2"></a>

#### Published aim of the primary analysis

> “This study aimed to investigate the efficacy and safety of lysergic acid diethylamide (LSD)-assisted therapy in patients who experienced anxiety with or without association with a life-threatening illness.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.1-3"></a>

#### Aim of the long-term follow-up

> “We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness.”
> “We hypothesised effects would not be sustained up to the 12-month follow-up.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.1-4"></a>

#### Role in the development of DT120 (MM-120)

> “Data further validates MindMed's therapeutic approach and supports the clinical development of MM-120 for the treatment of Generalized Anxiety Disorder”
> “MindMed supports the UHB Liechti Lab in conducting investigator-initiated trials for LSD and other novel therapies and has exclusive access and rights to the data generated by these studies.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Study identifiers, dates, and status

| Item | Registry record |
| --- | --- |
| Brief title with acronym | “LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders (LSD-assist)” |
| Other study ID | “BASEC 2016-00992” |
| Phase | “Phase 2” |
| Study start (actual) | “2017-06-23” |
| Primary completion (actual) | “2021-12-15” |
| Study completion (actual) | “2021-12-15” |
| First posted | “2017-05-15” |
| Last update posted | “2021-12-22” |
| Results | “No Results Posted” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.2-2"></a>

#### Sites: two centers in Switzerland

> “This study has 2 locations”
> “Basel, Canton of Basel-City, Switzerland, 4056 University Hospital Basel”
> “Solothurn, Canton of Solothurn, Switzerland, 4500 Private Practice P.Gasser”
> “Sponsor University Hospital, Basel, Switzerland”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

> “The study was an investigator-initiated, two-centre trial, with one study centre at the University Hospital Basel, Switzerland, and the other study centre at the Clinic Dr Peter Gasser, Solothurn, Switzerland.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.2-3"></a>

#### Enrollment period, last visit, and follow-up completion

> “Enrolment began on 23 June 2017 and finished on 1 February 2021. The trial ended as planned, with the last patient visit on 15 December 2021. The assessment of follow-up questionnaires was completed by January 2023.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.2-4"></a>

#### First presentation of results, May 2022

> “These findings were presented in an oral presentation at London's PSYCH Symposium on May 11, 2022.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Official title and registered design

> “LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study”
> “Design: Double-blind, placebo-controlled random-order cross-over trial using two LSD (200 µg) and two placebo sessions with subjects acting as their own control.”
> “Interventional Model Description: randomized, double-blind, placebo-controlled, crossover”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

| Design element | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.3-2"></a>

#### Two-center, two-period, random-order crossover design

> “The study is an investigator-initiated 2-center trial that used a double-blind, placebo-controlled, 2-period, random-order, crossover design with 2 sessions with either oral LSD (200 μg) or placebo per period.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.3-3"></a>

#### Treatment periods, session spacing, and visit schedule

> “The order of administration was random and counterbalanced.”
> “After study inclusion, the participants were randomly assigned to LSD or placebo in the first treatment period and vice versa in the second treatment period by order of enrolment and group.”
> “As previously reported in detail, the study included a screening visit and two 24-week treatment periods per participant. Each treatment period consisted of two treatment sessions and five study visits. Treatment sessions were separated by 6 weeks (±2 weeks). Study visits were conducted at baseline, between treatment sessions, and 2, 8 and 16 weeks after the second treatment session. The last visit in the second period also served as the end-of-study visit.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

> “Patients were randomly assigned to two sessions with either oral LSD (200 µg) or placebo administration over a trial duration of 52 weeks per patient.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.3-4"></a>

#### Planned long-term follow-up by mailed questionnaire

> “Follow-up questionnaires were sent by mail to all participants (including dropouts) 12 months after the end-of-study visit.”
> “For those who received LSD in the first period, the follow-up was assessed 94 weeks after the last LSD treatment. For those who received placebo in the first period, the follow-up was assessed 68 weeks after the last LSD treatment.”
> “The follow-up was conducted 12 months after the end-of-study visit by post to investigate the same outcome measures as during the study, in which participants completed questionnaires about long-lasting effects and answered questions about adverse events.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.3-5"></a>

#### Funding, ethics approval, and licensing of the data to the developer of DT120

> “The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice and approved by the Ethics Committee of Northwest Switzerland (EKNZ), Swiss Federal Office for Public Health, and Swissmedic”
> “The study was funded by the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT). The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing the report. M.E.L. and P.G. are consultants for Mind Medicine, Inc.”
> “Knowhow and data associated with this work and owned by the University Hospital Basel were licensed by Mind Medicine, Inc., which had no role in financing, planning or conducting the present study or the present publication.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Age | “Age > 25 years.” |
| Anxiety diagnosis or severity | “Meet DSM-IV criteria for anxiety disorder as indicated by the Structured Clinical Interview for the DSM (SCID)-IV or have a score of at least 40 on the state- or trait STAI scale at study inclusion.” |
| Proportion with life-threatening illness | “40% or more of the participants should have a diagnosis of advanced-stage potentially fatal illness (autoimmune, neurological, or cancer without central nervous system (CNS) involvement).” |
| Life expectancy | “Patients should be ambulatory and not terminal and likely to have a roughly estimated life expectancy of > twelve months.” |
| Participants without life-threatening illness | “Patients without advanced-stage potentially fatal illness need to meet DSM-IV criteria for anxiety disorder (elevated STAI score not sufficient for inclusion)” |
| Psychiatric medication | “Participants are willing to refrain from taking any psychiatric medications during the experimental session period.” |
| Washout of antidepressants and anxiolytics | “If they are being treated with antidepressants or are taking anxiolytic medications on a fixed daily regimen such drugs must be discontinued long enough before the LSD/placebo treatment session to avoid the possibility of a drug-drug interaction (the interval will be at least 5 times the particular drug's half-life [typically 3-7 days]).” |
| Ongoing psychotherapy | “If in ongoing psychotherapy, those recruited into the study may continue to see their outside therapist, provided they sign a release for the investigators to communicate directly with their therapist.” |
| Other psychoactive drugs | “Participants must also refrain from the use of any psychoactive drugs, with the exception of the long term pain medication or caffeine or nicotine, within 24 hours of each LSD/placebo treatment session.” |
| Driving | “Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD/placebo administration.” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.4-2"></a>

#### Exclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Pregnancy and contraception | “Women who are pregnant or nursing, or of child bearing potential and are not practicing an effective means of birth control” |
| Psychotic disorder | “Past or present diagnosis of a primary psychotic disorder.” |
| Family history of psychosis | “Subjects with a first degree relative with psychotic disorders are also excluded.” |
| Bipolar disorder | “Past or present bipolar disorder (DSM-IV)” |
| Substance use disorder | “Current substance use disorder (within the last 2 months, DSM-V, except nicotine)” |
| Somatic disorders | “Somatic disorders including central nervous system (CNS) involvement of the cancer, severe cardiovascular disease, untreated hypertension, severe liver disease (liver enzymes increase by more than 5 times the upper limit or normal) or severely impaired renal function (estimated creatinine clearance <30 ml/min)” |
| Body weight | “Weight < 45 kg” |
| Suicide risk | “Suicide risk or likely to require psychiatric hospitalization during the course of the study” |
| Concomitant psychotropic therapy | “Requiring ongoing concomitant therapy with a psychotropic drug (other than as needed, anxiety medications, and pain control medications) and unable or unwilling to comply with the washout period.” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.4-3"></a>

#### Anxiety disorder diagnoses eligible, including generalized anxiety disorder

> “The goal was to include people with anxiety disorders or significant anxiety that was associated with LTI. LTI was defined as any severe somatic disease, such as a diagnosis of cancer or another advanced-stage potentially fatal illness.”
> “criteria for an anxiety disorder, including generalised anxiety disorder, social phobia and panic disorder, as indicated by the Structured Clinical Interview for the DSM-IV (SCID-IV), or have a score ≥40 on the state or trait STAI at study inclusion. Participants without LTI had to meet DSM-IV criteria for at least one anxiety disorder. Thus, in people without LTI, elevated STAI scores were not sufficient for inclusion.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.4-4"></a>

#### Recruitment

> “Participants were recruited through an advertisement that was placed on website homepages of the University Hospital Basel and Swiss Medical Society for Psycholytic Therapy (SAePT) trial registries, or by word of mouth.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Registered interventions

| Intervention | Quoted registry text |
| --- | --- |
| LSD | “Lysergic Acid Diethylamide 200ug per os, single dose” |
| Placebo | “Capsules containing mannitol looking identical to LSD” |
| Arm sequence | “Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.5-2"></a>

#### Study drug and placebo as described in the follow-up publication

> “LSD free base (>99% purity; Lipomed AG, Arlesheim, Switzerland) was administered as an oral solution in units that contained 100 μg LSD in 1 mL of 96% ethanol. Inactive placebo consisted of identical units that were filled with ethanol only.”
> “Randomisation and production were performed according to good manufacturing practice (GMP) by a licensed GMP facility (Apotheke Dr Hysek, Biel, Switzerland).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.5-3"></a>

#### Session setting, duration, and therapist

> “After successful screening, each person was assigned for the entire duration of the study to one investigator/therapist who conducted all treatment sessions and study visits. Treatment sessions lasted approximately 12 h, and study visits lasted approximately 1 h. Study visits consisted of talk therapy, followed by an assessment of adverse events, changes in general medication and administration of the questionnaires.”
> “Treatment sessions were conducted in a calm hospital room (University Hospital Basel) or calm practice room (Clinic Dr Peter Gasser). Only one participant and one investigator/therapist were present during the treatment sessions (exceptions of more than one therapist being present were made upon request by the therapist or participant).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.5-4"></a>

#### Background treatment: LSD given as an add-on

> “However, most people had already received some therapy (e.g. anxiolytics, antidepressants or talking psychotherapy) when they entered the trial, and antidepressant treatment was only tapered off for LSD/placebo sessions.”
> “LSD therapy therefore served as an add-on for those who had already received treatment at trial inclusion.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.5-5"></a>

#### Additional psychedelic sessions after the trial

> “Six individuals from the original study continued psychedelic therapy (LSD, 3,4-methylenedioxymethamphetamine (MDMA) or psilocybin) within the Swiss limited-use programme and underwent one to four additional psychedelic sessions (all LSD).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using State-Trait Anxiety Inventory Global Score as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Registered primary and secondary outcomes

| Outcome | Quoted registry text |
| --- | --- |
| Primary | “Reduction in anxiety assessed by questionnaires (STAI) 16 weeks after LSD compared with placebo” |
| Primary time frame | “16 weeks post-intervention” |
| Secondary: depression | “Reduction in depression will be assessed by questionnaires (HDRS, BDI) 2, 8 and 16 weeks after LSD compared with placebo” |
| Secondary: anxiety at earlier visits | “Reduction in anxiety will be assessed by questionnaire (STAI) 2 and 8 weeks after LSD compared with placebo” |
| Secondary: psychopathology | “Reduction of psychopathological symptoms will be assessed by questionnaire (SCL-90) 2, 8, and 16 weeks after LSD compared with placebo” |
| Secondary: sustained response | “Follow-up using different questionnaires to compare (within-subject) the 52-week response with Responses from baseline and 16-weeks.” |

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.6.1-2"></a>

##### Primary endpoint as published: STAI-Global score at 16 weeks

> “The primary end point was anxiety symptoms 16 weeks after the last treatment session, assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients. Further outcome measures included ratings for depression symptoms (Beck Depression Inventory and Hamilton Depression Rating Scale, 21-item version) and ratings for acute subjective drug effects.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.6.1-3"></a>

##### Purpose of the STAI global score as stated by the sponsor

> “The primary efficacy endpoint was reduction in anxiety symptoms 16 weeks after the last LSD or placebo administration. The primary outcome measure was the State Trait Anxiety Inventory (STAI) global score, which is used to assess the severity of anxiety symptoms.”
> “Secondary outcome measures included improvements in Hamilton Depression Scale (HAM-D), Beck Depression Index (BDI), and several other major psychiatric symptoms (Symptom-Check-List-90-R) scores.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.6.1-4"></a>

##### Response and remission definitions

> “The clinical response was defined as a STAI-G reduction ≥ 30%.”
> “Remission was defined as score <80 for the STAI-G.”
> “Remission was defined as score <10 for the BDI; only patients with a score of ≥10 at screening were included.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.6.1-5"></a>

##### Outcome measures of the long-term follow-up

> “The primary outcome measure in the present study was defined the STAI-G (with the primary end-point 16 weeks after the last treatment session, as reported previously).”
> “Secondary outcomes that were assessed during the study and at the follow-up were scores on the STAI-State (STAI-S), STAI-Trait (STAI-T), BDI and SCL-90-R.”
> “At follow-up, in addition to the therapeutic outcome questionnaires, a questionnaire about persisting effects of psychedelics was administered.”
> “Personality traits at screening and the 1-year follow-up were assessed using the 60-item NEO - Five-Factor Inventory (NEO-FFI)”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned sample in the registered summary

> “Participants: 40 patients aged > 25 years with anxiety disorder (according to DSM-IV or a state-trait anxiety inventory score >40 in the STAI trait or state scale) with or without life-threatening illness.”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

<a id="topic-3.1.4.7.1-2"></a>

##### Enrolled: 46 participants

> “Enrollment (Actual) 46”

Source: [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)

> “The trial enrolled 46 patients either suffering from anxiety symptoms in life-threatening illnesses or with an anxiety disorder without severe somatic illness.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.7.1-3"></a>

##### Analyzed in the primary analysis: 42 participants

> “assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.7.1-4"></a>

##### Analyzed at long-term follow-up

> “Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI). People who had at least two LSD sessions and one outcome measure were included in the analysis. One person did not complete the STAI questionnaires, resulting in a total of 33 people for all STAI measures and 34 people for all other measures. A total of 39 participants (20 in the LSD-first group and 19 in the placebo-first group) were eligible for the change-from-baseline analysis per treatment group.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Primary analysis restricted to the first period because of carryover

> “The outcomes for the first period (between-subjects analysis) are primarily shown due to carryover effects.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.7.2-2"></a>

##### Follow-up analysis set and statistical model

> “People who had at least two LSD sessions and one outcome measure were included in the analysis.”
> “Outcomes were analysed using Linear Mixed Effects models, employing the lme4 and lmer test packages in R. Time points were used as the fixed factor, and participants were used as the random factor. For therapeutic outcomes but not personality traits, baseline values of the periods were considered covariates (change from baseline values for the respective period).”
> “Tukey's post hoc pairwise comparisons of least square means across time points were performed to elucidate significant differences between baseline and follow-up. These analyses were planned and hypothesised a priori in the protocol.”
> “Exploratory associations between the acute response to LSD and main follow-up outcome measures were assessed using Pearson's correlations.”
> “The criterion for significance was P < 0.05.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Enrolled and analyzed in the primary analysis

> “The trial enrolled 46 patients”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

> “assessed by the Spielberger State-Trait Anxiety Inventory-Global score in 42 patients”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.1-2"></a>

##### Participants contributing data at long-term follow-up

> “Detailed data on dropouts during the study were previously reported.”
> “Follow-up questionnaires were returned by 35 individuals (15 in the group with LTI and 20 without LTI).”
> “We received written feedback from 18 participants”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Duration of anxiety and prior treatment

> “On average, people were diagnosed with anxiety 10 ± 9 years (mean ± s.d.) prior to study inclusion (range: 0–39 years).”
> “Many of the participants in the present trial had a long history of treatment attempts/failures and were to some degree non-responsive chronic cases.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.2-2"></a>

##### Imbalance in symptom ratings between sequence groups

> “The most obvious difference between the two groups was that the placebo-first group had higher ratings in symptoms at inclusion, and this coincidental difference remained throughout the entire trial.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.2-3"></a>

##### Personality trait openness at study inclusion

> “Interestingly, the individuals in the present study had very high values in the trait openness at study inclusion compared with reference values from the general population”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Primary endpoint: STAI-Global change at 16 weeks (between-subjects analysis)

> “LSD treatment resulted in significant reductions of State-Trait Anxiety Inventory-Global scores up to 16 weeks after treatment (least-square mean [standard error] change from baseline difference = -16.2 [5.8], 95% CI, -27.8 to -4.5, d = -1.18, p = .007).”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.3-2"></a>

##### Depression: HAM-D-21 and BDI

> “Similar effects were observed for ratings of comorbid depression on the Hamilton Depression Rating Scale, 21-item version (-7.0 [1.9], 95% CI, -10.8 to -3.2, d = -1.1, p = .0004) and the Beck Depression Inventory (-6.1 [2.6], 95% CI, -11.4 to -0.9, d = -0.72, p = .02).”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.3-3"></a>

##### STAI-G response and time course reported at the oral presentation

> “A clinical response (reduction in STAI-G scores ≥30%) was observed in 65% (13/20) patients in the LSD arm and in 9% (2/22) patients in the placebo arm (p=0.003). Effects were maximal 2 weeks after the second LSD session and sustained up to 16 weeks.”
> “All secondary endpoint measurements, including the HAM-D-21, BDI, and SCL-90-R, showed similarly rapid and sustained responses consistent with a lasting treatment effect on anxiety, depression, and general psychiatric symptomatology.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.8.3-4"></a>

##### Acute subjective effects and long-term anxiety reduction

> “Positive acute subjective drug effects and mystical-type experiences correlated with the long-term reductions in anxiety symptoms.”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

> “Correlations between acute LSD effects and long-term outcomes showed a significant correlation between ΔSTAI-G measures and mystical-type experiences (total MEQ30 score; r p = −0.342, P = 0.048)”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-5"></a>

##### Follow-up at 12 months after the end-of-study visit: STAI-G change from baseline

> “Participants reported a sustained reduction of STAI-G scores compared with baseline (least square means (95% CI) = −21.6 (−32.7, −10.4), d = 1.04, P < 0.001, for those who received LSD in the first period (94 weeks after the last LSD treatment) and −16.5 (−26.2, −6.8), d = 1.02, P < 0.05, for those who received LSD in the second period (68 weeks after the last LSD treatment)).”
> “The LSD-first group improved significantly on the STAI-G compared with the primary end-point (16 weeks after last drug administration) at follow-up. The least square mean (95% CI) change was −9.7 (−15.5, −4.0), while the placebo-first group showed no further improvement: 1.2 (−4.2, 6.6).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-6"></a>

##### Follow-up at 12 months: depression

> “Similar effects were observed for comorbid depression with change from baseline BDI scores of −8.1 (−13.2, −3.1), d = 0.71, P < 0.01, and −8.9 (−12.9, −4.9), d = 1.21, P < 0.01, for the LSD-first and placebo-first groups, respectively.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-7"></a>

##### Follow-up at 12 months: remission and response

> “At follow-up, a total of 11 participants (33%) were in remission with regard to anxiety symptoms, and a total of 17 participants (49%) were in remission with regard to depression symptoms”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

| Follow-up row (Table 2, week 102) | LSD first, % | LSD first, n | Placebo first, % | Placebo first, n | All, % | All, n |
| --- | --- | --- | --- | --- | --- | --- |
| STAI-G remission (score <80) | “56” | “9” | “12” | “2” | “33” | “11” |
| STAI-G response (reduction of ≥30%) | “56” | “9” | “35” | “6” | “45” | “15” |
| BDI remission (score <10) | “56” | “9” | “42” | “8” | “49” | “17” |

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.3-8"></a>

##### Subgroups: life-threatening illness, further psychedelic therapy, and generalized anxiety disorder

> “Post hoc tests revealed no significant differences between people with and without LTI (P = 0.45 for the LSD-first group and P = 0.41 for the placebo-first group), people whose therapy was continued within the Swiss limited-use programme (P = 0.89 for the LSD-first group and P = 0.66 for the placebo-first group) and people with a formal diagnosis of generalised anxiety disorder (GAD; P = 0.35 for the LSD-first group and P = 0.65 for the placebo-first group).”
> “The present study included participants with a range of anxiety diagnoses that were included based on their symptom severity; this approach is supported by the findings that we found no difference in response between the groups (LTI versus non-LTI) and diagnosis (GAD versus non-GAD).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

##### Persisting Effects Questionnaire at follow-up

> “On the PEQ, high ratings of positive attitudes about life and/or self, positive mood changes, altruistic/positive social effects and positive behavioural changes were reported (all >47% of the total maximum score), whereas ratings of the negative counterparts remained low (all <10% of the total maximum score).”
> “On average, people rated the experience as ‘among the ten most personally meaningful experiences in life’, as ‘very much’ spiritually meaningful and as having positively influenced their sense of well-being or life satisfaction”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.4-2"></a>

##### Personality traits (NEO Five-Factor Inventory)

> “Personality trait neuroticism decreased (P < 0.0001) and trait extraversion increased (P < 0.01) compared with study inclusion.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.4-3"></a>

##### General psychiatric symptoms (SCL-90-R)

> “Participants reported sustained reductions of anxiety, depression and general psychiatric symptomatology up to 12 months after the end-of-study visit compared with baseline measures”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.8.4-4"></a>

##### Written participant feedback at follow-up

> “We received written feedback from 18 participants, which included the following topics: therapeutic potential of LSD (14 participants; 13 positive, one negative), setting and atmosphere (five participants; three positive, two negative), guide/therapist interaction (two participants; one positive, one negative), dose-related feedback (two participants; both negative (one participant reported the dose was too high, and one participant reported the dose was too low)), post-session effects (two participants; one positive, one negative) and comparison between dosing days (one participant; negative).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Acute untoward effects and treatment-related serious adverse event

> “Transient, mild, acute untoward effects of LSD treatment were reported by 8 patients (19%). One treatment-related serious adverse event (acute transient anxiety) occurred (2%).”

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)

<a id="topic-3.1.4.8.5-2"></a>

##### Serious adverse event description and suicidality

> “LSD was well-tolerated: only one SAE was considered related to treatment and consisted of acute transient anxiety and delusions during an LSD session. There were no recorded instances of treatment-emergent suicidal ideation with intent, suicidal behavior or intentional self-injury.”

Source: [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.8.5-3"></a>

##### Long-term safety: flashbacks and hallucinogen persisting perception disorder

> “Additionally, the follow-up questionnaire included questions about adverse effects, including flashbacks and hallucinogen persisting perception disorder (HPPD; see Supplemental Information for detailed questions)”
> “No additional adverse events were reported in the follow-up period, and no additional clinically relevant flashback phenomena or HPPD occurred.”
> “LSD did not induce any long-term adverse events, such as flashbacks or HPPD.”
> “Lasting negative effects were minimal.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

NCT03153579 was an investigator-initiated phase 2 crossover trial at two centers in Switzerland (University Hospital Basel and a private practice in Solothurn), funded by University Hospital Basel and the Swiss Medical Society for Psycholytic Therapy. The registered summary planned 40 participants; 46 were enrolled, and 42 were included in the primary analysis. Because of carryover effects, the primary results are a between-subjects comparison of the first period, in which a STAI-G response (reduction of 30% or more) was reported for 13 of 20 participants (65%) receiving LSD and 2 of 22 (9%) receiving placebo. The response figures come from the May 2022 company announcement of an oral presentation; the primary publication reports the least-squares mean difference of -16.2 points (95% CI, -27.8 to -4.5) at 16 weeks.

The population combined participants with an anxiety disorder and participants with anxiety associated with a life-threatening illness, for whom a STAI score of 40 or more could substitute for a DSM-IV diagnosis; eligible diagnoses included generalized anxiety disorder, social phobia, and panic disorder, and the follow-up post hoc tests found no difference in STAI-G change between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The primary endpoint was a self-reported questionnaire, and the follow-up authors state that no objective, interview-based data and no measure of expectancy were collected. The placebo-first group had higher symptom ratings at inclusion, a difference that remained throughout the trial.

Each participant received LSD 200 μg in two sessions of approximately 12 hours with one investigator or therapist, and study visits included talk therapy. The follow-up publication describes the study drug as LSD free base in an oral solution of 96% ethanol (100 μg per mL) with an ethanol-only placebo, while the registry describes placebo capsules containing mannitol. Most participants had received anxiolytics, antidepressants, or psychotherapy before entry, antidepressants were tapered only for the sessions, and the authors state that LSD served as an add-on treatment; the participants were described as having a long history of treatment attempts and failures, with anxiety diagnosed a mean of 10 years before inclusion.

The 12-month follow-up had no control group, since all participants had received LSD by then. Questionnaires were returned by mail by 35 participants, with 33 contributing STAI measures, and 6 participants continued psychedelic therapy in the Swiss limited-use programme with one to four additional LSD sessions. The authors state that it is largely unclear what therapy participants received between the end-of-study visit and follow-up. The primary publication reports transient, mild acute untoward effects in 8 participants (19%) and one treatment-related serious adverse event of acute transient anxiety (2%), which the company announcement describes as acute transient anxiety and delusions. The registry has no posted results.

Two authors are consultants for Mind Medicine, Inc., which licensed the knowhow and data owned by University Hospital Basel; the authors state that the company had no role in financing, planning, or conducting the follow-up study, and the company states that it has exclusive access and rights to the data.

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/); [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/); [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579); [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)

<a id="topic-3.1.4.9-2"></a>

#### Limitations stated by the authors of the follow-up

> “The present study also has limitations. The present analysis included no control group for long-term effects of LSD. Additionally, no objective, interview-based data were collected, the herein-reported data are based on self-report questionnaires and no measure of expectancy was collected. All participants received LSD within this crossover study. Lasting effects were compared with measures before LSD-assisted therapy over time and within subjects. Therefore, we cannot exclude the possibility that other factors contributed to the long-term effects. Furthermore, it is largely unclear what therapy people received between the end-of-study visit and the follow-up.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.9-3"></a>

#### Treatment expectancy and differences between sequence groups

> “However, it remains unclear why individuals in the LSD-first group appeared to benefit more from LSD-assisted therapy compared with those who received placebo first.”
> “This also raises a question about treatment expectancy and whether people in the placebo-first group felt disadvantaged by not receiving LSD in the first period and whether this motive remained intact and influenced the subsequent therapeutic response.”
> “Also, the two placebo sessions in the second period could have served as additional integration sessions in those who received LSD in the first period.”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

<a id="topic-3.1.4.9-4"></a>

#### Additional sessions outside the trial

> “There was no significant difference in the primary treatment outcome (STAI-G) at follow-up compared with those who had no further psychedelic-assisted therapy, although an important consideration is the small sample size (n = 6).”

Source: [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
